Metrics as of 10/14/2026, 09:27 PM (Berlin time), refresh in progress.
AtriCure Stock
AtriCure, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Michael H. Carrel
- Employees
- 1,350
- Market cap
- $2.9 B
- IPO
- 05/08/2005
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Headquartered in Mason, USA, the company was founded in 2000 and operates within the Healthcare sector. Its market reach spans the United States, Europe, Asia, and other international…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
AtriCure stock: price history
1D
-3.0%
1W
+0.5%
1M
-1.9%
6M
+88.7%
YTD
+41.7%
1Y
+50.6%
2Y
+92.3%
5Y
-21.4%
10Y
+230.0%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~25% stronger price swings than usual
AtriCure stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
AtriCure is a medical device company specializing in surgical treatment of cardiac tissue and intercostal nerves. Its product portfolio comprises various ablation technologies, including single-use radiofrequency products, cryoablation systems, and implantable solutions such as the AtriClip system. The business model is primarily based on the sale of surgical instruments and highly specialized disposable materials (single-use) that are essential for performing these procedures, thereby generating a high rate of recurring revenue. Products are distributed through both an internal sales team and independent distributors across various international markets, with the USA accounting for the largest share.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about AtriCure
Analyst assessment of AtriCure
PRICE TARGET LOW
US$50.00
CONSENSUS
US$57.29
MEDIAN
US$55.00
PRICE TARGET HIGH
US$65.00
0
STRONG BUY
18
BUY
2
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 12/10/2026
AtriCure stock metrics
P/E
270.44
P/B
5.39
EV/EBITDA
74.8
RETURN ON EQUITY
1.7%
NET MARGIN
5.8%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.9%
FLOAT SHARES
48,764,148
AVG. DAILY VOLUME (30D)
1,354,720
Insider transactions (SEC)
Privitera Salvatore
GROVES REGINA E
Privitera Salvatore
Privitera Salvatore
Dahlquist Karl S.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about AtriCure stock
What does AtriCure do?
AtriCure, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Michael H. Carrel, the company employs around 1,350 people.
The IPO was on 05/08/2005; the stock trades on NASDAQ under the ticker ATRC.
What do analysts say about AtriCure stock?
20 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$57.29, ranging from US$50.00 to US$65.00, with a median of US$55.00.
This is an external assessment, not a statement by Market Jury.
When does AtriCure report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does AtriCure pay a dividend?
No, AtriCure currently does not pay a dividend.
Which stocks are comparable to AtriCure?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get AtriCure stock analyzed?
Clicking "Analyze stock" lets five strategies assess AtriCure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.